Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 12/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 10/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584173 | 0.96 | NTSR1 (0.53) | AGTR2AGTR1NTSR1NTSR2NPY1R | |
| SCHEMBL30584175 | 0.91 | NTSR1 (0.52) | AGTR2AGTR1NTSR1NTSR2NPY1R | |
| SCHEMBL30584174 | 0.90 | NTSR1 (0.66) | NTSR1NTSR2SORT1 | |
| SCHEMBL30584172 | 0.89 | NPY1R (0.59) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL30584178 | 0.89 | NTSR1 (0.59) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL30584176 | 0.86 | NTSR1 (0.66) | NTSR1NTSR2SORT1 | |
| SCHEMBL30584171 | 0.86 | NTSR1 (0.60) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL30584170 | 0.85 | NTSR1 (0.59) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29496659 | 0.83 | NTSR1 (0.56) | AGTR2AGTR1NTSR1NTSR2NPY1R | |
| SCHEMBL31556390 | 0.82 | NTSR1 (0.56) | AGTR2AGTR1NTSR1NTSR2NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265124-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265124-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | OXTR, AVPR2, ADM2 | AGTR2 136/4885AGTR1 230/4885NTSR1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.